MSB 2.17% $1.13 mesoblast limited

Ryoncil: ODAC/FDA Meeting Discussion, page-999

  1. 6 Posts.
    They're not disputing safety. Still questioning efficacy, though stated "the FDA is concerned about missing the opportunity to make a new therapy available" - sounds promising.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.